Clinical Trials Logo

Recurrent Childhood Ependymoma clinical trials

View clinical trials related to Recurrent Childhood Ependymoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05857969 Recruiting - Clinical trials for Recurrent Childhood Acute Lymphoblastic Leukemia

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Start date: February 22, 2023
Phase:
Study type: Observational

Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and genomic profiling to determine the optimal individualized therapy for cancer patients. In this study, we will enroll relapsed or refractory pediatric cancer patients with tissue available for DST and genomic profiling from the South Florida area, which is 69% Hispanic and 18% Black. Tumor cells collected from tissue taken during routine biopsy or surgery will be tested.

NCT ID: NCT02359565 Recruiting - Malignant Glioma Clinical Trials

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

Start date: May 22, 2015
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of pembrolizumab and to see how well it works in treating younger patients with high-grade gliomas (brain tumors that are generally expected to be fast growing and aggressive), diffuse intrinsic pontine gliomas (brain stem tumors), brain tumors with a high number of genetic mutations, ependymoma or medulloblastoma that have come back (recurrent), progressed, or have not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may induce changes in the body's immune system, and may interfere with the ability of tumor cells to grow and spread.